4.5 Article

The association of interleukin-16 gene polymorphisms with susceptibility of coronary artery disease

Journal

CLINICAL BIOCHEMISTRY
Volume 46, Issue 3, Pages 241-244

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2012.11.009

Keywords

IL-16; Polymorphism; Haplotype; Coronary artery disease

Ask authors/readers for more resources

Objectives: Recent studies have shown that interleukin (IL)-16 is an immunomodulatory cytokine, which plays an important role in some inflammatory and autoimmune diseases. We aimed to investigate the association between the IL-16 gene polymorphisms and presence of coronary artery disease (CAD) where inflammatory processes are involved. Designs and Methods: This case-control study enrolled 651 CAD patients confirmed by coronary angiography and 428 controls. Four tag single nucleotide polymorphisms (rs8034928-rs3848180-rs4577037-rs1131445) within the IL-16 gene and the related haplotypes were genotyped by using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). Plasma IL-16 concentration was measured by enzyme-linked immunosorbent assay. Results: In patients with CAD, the plasma concentration of IL-16 was significantly higher than in controls (97.6 +/- 10.7, 66.5 +/- 9.6, respectively P<0.001). By using multivariate logistic regression analysis, the allele and genotype frequencies of rs8034928 were different between CAD and control groups (P<0.001). However, the associations of the polymorphisms rs3848180, rs4577037, and rs1131445 with CAD were not observed. The haplotypes 1111 and TGGT significantly increased risk to CAD (OR, 95% CI: 1.43, 126-1.63; 1.47, 1.16-1.85; respectively), whereas the haplotypes CTTT and TTGT referred to protection of CAD (OR, 95% CI: 0.45, 033-0.62; 0.50, 033-0.76; respectively). Conclusion: The study indicated that the IL-16 rs8034928 T/C polymorphism and haplotypes were associated with the presence of CAD in Chinese Han population. The IL-16 gene polymorphisms may be a useful predictor to the susceptibility of CAD. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available